CN103520711A - Formula composition and medicinal preparation with effects of increasing bone density and treating bone joint pain, preparation method of medicinal preparation and application of formula composition - Google Patents
Formula composition and medicinal preparation with effects of increasing bone density and treating bone joint pain, preparation method of medicinal preparation and application of formula composition Download PDFInfo
- Publication number
- CN103520711A CN103520711A CN201310507876.0A CN201310507876A CN103520711A CN 103520711 A CN103520711 A CN 103520711A CN 201310507876 A CN201310507876 A CN 201310507876A CN 103520711 A CN103520711 A CN 103520711A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- preparation
- bone density
- pharmaceutical preparation
- bone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to the field of medicines and health care food, and particularly relates to a formula composition and a medicinal preparation with effects of increasing bone density and treating bone joint pain, a preparation method of the medicinal preparation and an application of the formula composition. The formula composition comprises N-sulfo-glucosamine potassium salt, calcium carbonate, collagen, fructus psoraleae extractive, and casein phosphopeptides. The formula composition can be prepared into various dosage forms to be used as medicines or health care food. The formula composition and the medicinal preparation thereof can effectively increase bone cell proliferation and the bone density, prevent various kinds of discomfort caused by bone loss and relieve bone joint pain, and have no toxic or side effects.
Description
Technical field
The present invention relates to medicine and field of health care food, be specifically related to a kind of compound composition, pharmaceutical preparation, preparation method and its usage that increases bone density, treatment bone joint pain effect that have, compound composition of the present invention and pharmaceutical preparation and the product preparing according to preparation method of the present invention can be prepared as medicine or health food.
Background technology
Osteoporosis is a kind of systemic osteopathia, it is characterized in that bone amount declines and the fine structure of bone destroys, and the fragility that shows as bone increases, and then causes the danger of fracture to greatly increase, even also easily fracture in slight wound or atraumatic situation.Osteoporosis is a kind of chronic disease due to multifactor.Before fracture occurs, conventionally without Special Clinical Manifestation.Along with the increase of China's aging population, osteoporosis sickness rate is all a health problem meriting attention in ascendant trend ， China and even the whole world.
For a long time, osteoporosis is not valued by the people, and existing increasing middle-aged and elderly people is deeply hurt at present, and also there are some researches prove can be by increasing bone density prevention and the loose disease for the treatment of sclerotin.
Bone density, full name is skeleton mineral density, is an important indicator of bone strength, with gram/every square centimeter of expression, when clinical use bone density value, because the absolute value of different bone mineral density detectors is different, conventionally use T value to judge that whether bone density normal.In prior art, often by simple supplement calcium or conciliation endocrine, promote calcareous absorption to increase the bone density of skeleton.But mode is single.
Thus, need to provide a kind of can increase bone density, the compound composition of alleviation and treatment arthralgia, pharmaceutical preparation, preparation method and preparation method thereof.
Summary of the invention
In view of this, in first aspect, the invention provides and have the compound composition that increases bone density, treatment bone joint pain effect, described compound composition is comprised of the raw material of following weight portion:
D-glucosamine sulphuric acid potassium salt 60-90 part, calcium carbonate 35-65 part, ossein 10-40 part, Fructus Psoraleae extract 10-25 part, phosphopeptide caseinate 2-8 part.
Preferably, the described raw material by having the following weight portion of compound composition that increases bone density effect forms:
75 parts of D-glucosamine sulphuric acid potassium salt, 50 parts of calcium carbonate, 25 parts of osseins, 15 parts of Fructus Psoraleae extracts, 4 parts of phosphopeptide caseinates.
Preferably, in described Fructus Psoraleae extract, contain percentage by weight and be more than or equal to 1% psoralen.
In second aspect, the present invention also provides a kind of pharmaceutical preparation that increases bone density, treatment bone joint pain effect that has, and it is comprised of compound composition and the solid pharmacy adjuvant with increase bone density effect as above; Described solid pharmacy adjuvant weight is no more than 25% of described pharmaceutical preparation weight.
Also, as the compound composition of its constitutive material, the raw material by following weight portion forms: D-glucosamine sulphuric acid potassium salt 60-90 part, calcium carbonate 35-65 part, ossein 10-40 part, Fructus Psoraleae extract 10-25 part, phosphopeptide caseinate 2-8 part.
Preferably, described pharmaceutical preparation is pill, granule, capsule, tablet or powder.
Preferably, described solid pharmacy accessory package is drawn together wherein any one or any two s' mixture of starch, dextrin, microcrystalline Cellulose, hydroxy methocel, magnesium stearate.
Preferably, described solid pharmacy accessory package is drawn together starch and magnesium stearate.
In the third aspect, the present invention also provides a kind of method of preparing said medicine preparation, and described method comprises:
Get the Fructus Psoraleae extract of 10-25 weight portion and the phosphopeptide caseinate of 2-8 weight portion, after mistake 80 mesh sieves, mix homogeneously obtains the first mixed powder respectively;
Get the ossein of 10-40 weight portion, the starch of 20-30 weight portion, excessively after 80 mesh sieves, mix homogeneously and obtain the second mixed powder with described the first mixed powder respectively;
Get the D-glucosamine sulphuric acid potassium salt of 60-90 weight portion, after pulverizing, cross 80 mesh sieves and obtain D-glucosamine sulphuric acid potassium salt powder; Get the calcium carbonate of 35-65 weight portion, excessively after 80 mesh sieves, mix with described D-glucosamine sulphuric acid potassium salt powder and described the second mixed powder and obtain total mixed powder;
Get the starch of 2-3 weight portion, add purified water configuration starch slurry, described starch slurry and total mixed powder mix and blend are obtained to soft material;
After described soft material is fabricated to soft material granule, dry acquisition mixed composition granule;
Get the magnesium stearate of 0.5-1 weight portion, excessively after 80 mesh sieves, mix with dried mixed composition granule and obtain total mixed material;
Utilize described total mixed material by predetermined dosage form useful in preparing drug formulations.
Fourth aspect, the present invention also provides above-mentioned compound composition in preparation prevention and the medicine for the treatment of osteoporosis or the application in health food
Compound composition of the present invention and pharmaceutical preparation and the pharmaceutical preparation preparing according to preparation method of the present invention can effectively increase bone density, alleviate and treatment arthralgia, have no side effect, can long-term taking, it can be prepared as medicine or health food, and be widely used in mid-aged population, prevent and treat the osteoporosis causing due to bone-loss.
The specific embodiment
Below by the specific embodiment, further illustrate technical scheme of the present invention.The description that it will be appreciated by those skilled in the art that this part is not limited to the present invention, and to those skilled in the art, the present invention can have various changes and variation.All any modifications of doing, be equal to replacement, improvement etc., within protection scope of the present invention all should be included within spirit of the present invention and principle.
Embodiment mono-
The present embodiment provides a kind of compound composition that increases bone density, treatment bone joint pain effect that has, and it can increase skeleton density, prevents osteoporosis, treatment bone joint pain.The compound composition of the present embodiment is comprised of the raw material of following weight portion:
D-glucosamine sulphuric acid potassium salt 60-90 part, calcium carbonate 35-65 part, ossein 10-40 part, Fructus Psoraleae extract 10-25 part, phosphopeptide caseinate 2-8 part.
Wherein, D-glucosamine sulphuric acid potassium salt, also referred to as Glucosamine sulfate potassium chloride, English name is " N-Sulfo-glucosamine potassium salt ", we find under study for action, glucosamine and oligochitosan are changed by obvious inhibitory action too high bone, and can improve skeleton and build ability again, for removal ovary, cause osteoporosis by obvious antagonism.
In the contrast experiment of glucosamine, 2-Acetamido-2-deoxy-D-glucose, oligochitosan, carboxymethyl chitosan oligosaccharide, four kinds of sugar all have the effect of obvious promotion osteocyte propagation, and wherein glucosamine is best for the facilitation of bone propagation.
Calcium is one of the abundantest inorganic elements of people's in-vivo content, accounts for the 1.5%-2% of body weight, wherein 99% calcareous being present in human skeleton and tooth.Bone is comprised of Organic substance and inorganic matter, and Organic substance is mainly protein, makes bone have certain toughness, and inorganic matter to be mainly calcareous and phosphorus matter make bone have certain hardness, during calcium loss in skeleton, bone density will reduce.Calcium carbonate is common calcium compounds, and osteoporosis refers to that calcium runs off gradually from skeleton, makes sclerotin attenuation, fluffs, becomes fragile.Calcium preparation is the basic medication for the treatment of osteoporosis.Human body can improve the calcium constituent amount of absorption by oral supplementation calcium preparation, thereby reduce to a certain extent skeleton, runs off, and increases bone density.
The ossein tectine matter that is otherwise known as, is be present in collagen protein in human body and animal body a kind of, is human articular cartilage, and epiphysial cartilage and bone trabecular Main Ingredients and Appearance, have 70%～86% in skeleton Organic substance, ossein.We study and find that ossein content reduces, and can cause reducing for bone mineralising provides the mechanical tenability of framework, make the inanimate matters such as calcium salt cannot deposit mineralising, cause bone loss and bone biomechanical strength decreased.To studies show that of osteoporosis patient, during osteoporosis, ossein content reduces and Quality Down.Ossein content declines has a rectilinear correlation with bone biomechanical intensity is low.Result of the test shows, ossein quantity reduces and Quality Down is to cause osteoporotic main cause.We study and find that research shows, osteoporosis is obviously relevant to the decline of ossein content, so treatment should suitably be replenished the calcium increasing on the basis of ossein content, make supplementary calcium salt have the basis of deposition mineralising.
Fructus Psoraleae, is also referred to as: Hu Semen Allii Tuberosi, the solid fat of mother-in-law are a kind of raw material of Chinese medicine, and it is acrid in the mouth in Chinese medicine theory; Bitter; Warm in nature, there is reinforcing the kidney and supporting YANG; Helping inspiration to relieve asthma; Warming spleen and stopping diarrha effect.
We have studied Fructus Psoraleae water extraction liquid and the impact of psoralen on osteoblast cultured in vitro.Result of the test confirmation, Fructus Psoraleae water extraction liquid and psoralen have the effect of phytoestrogen sample, can promote osteoblastic proliferation, impel cell by G<sub TranNum="98">1</sub>phase is to S phase, G<sub TranNum="99">2</sub>phase transforms.Meanwhile, we have also observed Fructus Psoraleae water decoction and removal ovary sclerotin have been dredged to the impact of blue or green cytokine.Result demonstration, with sham operated rats comparison, model group rat blood serum estradiol, 1,25-dihydroxyvitamin D<sub TranNum="100">3</sub>level and bone density significantly reduce (P<0.01, P value is credible result level index in statistics).With model group comparison, Fructus Psoraleae group rat blood serum estradiol is still in lower water density, serum 1,25-dihydroxyvitamin D<sub TranNum="101">3</sub>, osteocalcin level obviously raises, and proved that thus Fructus Psoraleae water decoction can improve Ovariectomized Rats bone metabolism index and serum cytokines.
Meanwhile, we have also observed the Fructus Psoraleae soup of making laws with liver and kidney tonifying and the impact of the GUSONGBAO of making laws with kidney-replenishing on the bone density of patients with senile osteoporosis (S0P) (BMD), cytokine (TNF, IGF-II, IL-6).Data shows that above 3 kinds of cytokines have all participated in the pathology process of osteoporosis.The pathologic that Fructus Psoraleae soup can moderately reduce IL-6 and TNF increases, and moderately improves IGF-II value, and prompting Fructus Psoraleae soup turns into being one of its mechanism that affects bone metabolism, treatment osteoporosis the optimum of IL-6, TNF, IGF-II.
In a preferred implementation, in Fructus Psoraleae extract, contain percentage by weight and be more than or equal to 1% psoralen.
Phosphopeptide caseinate is to take bovine casein as raw material, and what by biotechnology, make has a bioactive polypeptide.Phosphopeptide caseinate in the small intestinal environment of animal can with the divalent minerals ions binding such as calcium, ferrum, zinc, selenium, prevent precipitation, strengthen the concentration of enteral dissolvable mine material, thereby promote to absorb, especially promote absorption and the utilization of calcium.We show by human experimentation result, and after the calcium tablet of the oral casein containing protein phosphoeptide of experimental group, twenty-four-hour urine calcium average improves nearly 9.7% than the urine calcium concentration of corresponding matched group, the two significant difference.Illustrate that phosphopeptide caseinate can significantly promote the absorption of human gastrointestinal tract to edible calcium.
Research shows, by increasing bone density, can alleviate significantly the various discomforts that cause due to bone-loss, alleviates and treatment arthralgia.
Compound composition described in the present embodiment is by mixing each raw material can prepare.
Described compound composition can be taken by oral way after being prepared as pharmaceutical preparation, and adult's human body dose of suggestion is 4g/ people's every day.
The present embodiment is by being used in conjunction with D-glucosamine sulphuric acid potassium salt, calcium carbonate, ossein, Fructus Psoraleae extract and phosphopeptide caseinate with the formula proportion of determining, wherein, D-glucosamine sulphuric acid potassium salt promotes the propagation of osteocyte, ossein, Fructus Psoraleae extract and phosphopeptide caseinate promote human body to calcareous absorption or improve calcareous utilization rate from different angles respectively, calcium carbonate increases human body for calcareous absorption simultaneously, calcareous from the absorption of the auxiliary raising of many aspects skeleton thus, improve bone density.The compound composition of the present embodiment can be prepared as medicine or the health food of pill, granule, capsule, tablet or powder form in conjunction with solid pharmacy adjuvant, it can effectively improve osteocyte propagation, improve bone density, alleviation and treatment arthralgia, effectively prevents and treat osteoporosis.
Embodiment bis-
Embodiment bis-provides a kind of compound composition that increases bone density, treatment bone joint pain effect that preferably has on embodiment mono-basis, and its raw material by following weight portion forms: 75 parts of D-glucosamine sulphuric acid potassium salt, 50 parts of calcium carbonate, 25 parts of osseins, 15 parts of Fructus Psoraleae extracts, 4 parts of phosphopeptide caseinates.
In a preferred implementation, in Fructus Psoraleae extract, contain percentage by weight and be more than or equal to 1% psoralen.
Compound composition described in the present embodiment is by mixing each raw material can prepare.
The described compound composition with increase bone density effect can be taken by oral way after being prepared as pharmaceutical preparation, and the human body dose of suggestion is 4g/ people/day every day.
The present embodiment is by being used in conjunction with D-glucosamine sulphuric acid potassium salt, calcium carbonate, ossein, Fructus Psoraleae extract and phosphopeptide caseinate with the optimization of C/C composites ratio of determining, in conjunction with solid pharmacy adjuvant, can be prepared as medicine or the health food of pill, granule, capsule, tablet or powder form, it can effectively improve osteocyte propagation, improve bone density, alleviation and treatment arthralgia,, effectively prevent and treat osteoporosis.
Embodiment tri-
Embodiment tri-provides a kind of pharmaceutical preparation based on compound composition described in embodiment mono-, and also, described compound composition is comprised of the raw material of following weight portion:
D-glucosamine sulphuric acid potassium salt 60-90 part, calcium carbonate 35-65 part, ossein 10-40 part, Fructus Psoraleae extract 10-25 part, phosphopeptide caseinate 2-8 part.
The pharmaceutical preparation of the present embodiment is comprised of above-mentioned formula combination raw material and solid pharmacy adjuvant; Described solid pharmacy adjuvant weight is no more than 25% of described pharmaceutical preparation weight.
Particularly, having described in embodiment mono-usingd in the pharmaceutical preparation of the present embodiment increases the compound composition of bone density effect as raw material, forms the pharmaceutical preparation of solid form in conjunction with solid pharmacy adjuvant, is convenient to take.The pharmaceutical preparation of the present embodiment can be prepared as pill, granule, capsule, tablet or powder to meet the various dosage form needs of taking.
In the present embodiment, solid pharmacy adjuvant can adopt and comprise wherein any one or any two s' mixture of starch, dextrin, microcrystalline Cellulose, hydroxy methocel, magnesium stearate.
In a preferred implementation, solid pharmacy adjuvant can be selected starch and magnesium stearate, and its weight portion can be chosen for respectively 30.4 parts and 0.6 part.
Pharmaceutical preparation described in the present embodiment is by each composition is mixed and can prepare preparation powder, then preparation powder is become to finished product preparation according to predetermined formulation, for example pill, granule, capsule, tablet or powder.
Described pharmaceutical preparation can be taken by oral way, and adult's human body dose of suggestion is every day 4
g/ people.
The present embodiment is by being used in conjunction with D-glucosamine sulphuric acid potassium salt, calcium carbonate, ossein, Fructus Psoraleae extract and phosphopeptide caseinate with the formula proportion of determining, in conjunction with solid pharmacy adjuvant, can be prepared as medicine or the health food of pill, granule, capsule, tablet or powder form, it can effectively improve osteocyte propagation, improve bone density, alleviation and treatment arthralgia, effectively prevents and treat osteoporosis.
Embodiment tetra-
Embodiment tetra-provides a kind of pharmaceutical preparation based on compound composition described in embodiment bis-, and also, described compound composition is comprised of the raw material of following weight portion:
75 parts of D-glucosamine sulphuric acid potassium salt, 50 parts of calcium carbonate, 25 parts of osseins, 15 parts of Fructus Psoraleae extracts, 4 parts of phosphopeptide caseinates.
The pharmaceutical preparation of the present embodiment is comprised of above-mentioned formula combination raw material and solid pharmacy adjuvant; Described solid pharmacy adjuvant weight is no more than 25% of described pharmaceutical preparation weight.
Particularly, having described in embodiment mono-usingd in the pharmaceutical preparation of the present embodiment increases the compound composition of bone density effect as raw material, forms the pharmaceutical preparation of solid form in conjunction with solid pharmacy adjuvant, is convenient to take.The pharmaceutical preparation of the present embodiment can be prepared as pill, granule, capsule, tablet or powder to meet the various dosage form needs of taking.
In the present embodiment, solid pharmacy adjuvant can adopt and comprise wherein any one or any two s' mixture of starch, dextrin, microcrystalline Cellulose, hydroxy methocel, magnesium stearate.
In a preferred implementation, solid pharmacy adjuvant can be selected starch and magnesium stearate, and its weight portion can be chosen for respectively 30.4 parts and 0.6 part.
The toxicity trial that pharmaceutical preparation based on this preferred implementation is carried out shows, the maximum tolerance value of the acute oral of rat (MTD) is greater than to 15g/kg.BW(body weight, Body Weight), sentence genus non-toxic type.Three hereditary poisonous substance experiments such as Ames(pollutant mutagenicity detection) experiment, mouse Bone marrow cells micronucleus experiment and mouse sperm deformity experiment are negative findings, show that pharmaceutical preparation of the present invention is without mutagenic action.Rat, within 30 days, in feeding trial, have no the ANOMALOUS VARIATIONS of animal health condition, biochemistry, hematological indices and organ-tissue form.
In the functional demonstration test of carrying out in the pharmaceutical preparation for the present embodiment.Adopt rat to test, rat uses normal feedstuff adaptability feed after seven days, according to body weight, be divided at random following five groups: low calcium matched group, high dose calcium carbonate group, three dosage groups of the present embodiment pharmaceutical preparation: 333.3mg/kg.BW group, 666.7mg/kg.BW group and 2000mg/kg.BW group, 14 of every treated animals.Five treated animals are all used low calcium feedstuff feed.Low calcium matched group is with distilled water gavage; Three dosage groups are with the sample liquid gavage (preparation of gavage liquid: get respectively the present embodiment pharmaceutical preparation 3.33g, 6.67g, 20g of preparation, adding distil water is settled to 100ml, is mixed with the gavage liquid of 333.3mg/kg.BW, 666.7mg/kg.BW, 2000mg/kg.BW group); High dose calcium carbonate control group per os pours into the calcium carbonate of 500mg/kg.BW, this dosage is equivalent to the present embodiment high doses group calcium level, and (the present embodiment sample calcium is 125g calcium carbonate/500g sample, in high dose group 2000mg/kg.BW, calcic is 200mg/kg.BW, and being converted into carbonic acid is 500mg/kg.BW.The preparation of gavage liquid: get calcium carbonate 5g adding distil water and be settled to 100ml).All animal gavage amounts are 10ml/kg.BW, and once a day, gavage is 90 days continuously, weigh weekly and adjust gavage amount by body weight.Test last femoral artery sacrificed by exsanguination animal, remove right side femur, in 105 degrees Celsius of baking ovens, bake to constant weight, weigh bone weight.Adopt the DPX-L type dual energy X-ray absorptiometry instrument of U.S. LUNAR company to measure fl density (g/cm2), its concrete assay method is to scan whole fl with DPX-L type dual energy X-ray absorptiometry instrument, represents the bone density of this bone with average bone density.Adopt the right femur calcium content of atomic absorption spectrophotometric determination.
Test data shows, there was no significant difference between the forward and backward body weight of experiment of three dosage groups and high dose calcium carbonate group and low calcium matched group (P > 0.05).Three dosage groups of the pharmaceutical preparation of the present embodiment and the lower calcium matched group of right femur bone weight average of high dose calcium carbonate group obviously increase (P < 0.05, P < 0.01), and concrete data can see table 1.
Table 1: the impact that the present embodiment pharmaceutical preparation weighs rat body weight, bone
Test data also shows, the fl bone density of high dose calcium carbonate group and basic, normal, high three the dosage groups of the present embodiment pharmaceutical preparation is all significantly higher than low calcium matched group (P < 0.01), and the right bone calcium content of femur higher dosage group calcium carbonate control group of high dose group obviously increases (P < 0.05), concrete data can see table 2.
Above data can absolutely prove according to the pharmaceutical preparation of recipe configuration of the present invention breeds by improving significantly osteocyte with respect to common supplement calcium or non-supplement calcium, increases the effect of bone density.
The present embodiment is by being used in conjunction with D-glucosamine sulphuric acid potassium salt, calcium carbonate, ossein, Fructus Psoraleae extract and phosphopeptide caseinate with the formula proportion of determining, in conjunction with solid pharmacy adjuvant, can be prepared as medicine or the health food of pill, granule, capsule, tablet or powder form, it can effectively improve osteocyte propagation, improve bone density, alleviation and treatment arthralgia, effectively prevents and treat osteoporosis.
Table 2: the impact of the present embodiment pharmaceutical preparation on rat bone density and calcium content of bone
Embodiment five
Embodiment five provides the side of the pharmaceutical preparation described in a kind of Preparation Example three preferred embodiments
Method, it optimizes the preparation stream of preparation in conjunction with pharmacology attribute and the physical features of various raw materials and batching
Journey, in the situation that guaranteeing properties of product optimum, enhances productivity.
Described preparation method comprises the steps:
The casein of step 100, the Fructus Psoraleae extract of getting 10-25 weight portion and 2-8 weight portion
Phosphoeptide, after mistake 80 mesh sieves, mix homogeneously obtains the first mixed powder respectively.
The starch of step 200, the ossein of getting 10-40 weight portion, 20-30 weight portion, excessively mixs homogeneously and obtains the second mixed powder with described the first mixed powder after 80 mesh sieves respectively.
It should be noted that, step 100 and step 200 are separate, and it can transposing order or parallel carrying out.
Step 300, get the D-glucosamine sulphuric acid potassium salt of 60-90 weight portion, after pulverizing, cross 80 mesh sieves and obtain D-glucosamine sulphuric acid potassium salt powder; Get the calcium carbonate of 35-65 weight portion, excessively after 80 mesh sieves, mix with described D-glucosamine sulphuric acid potassium salt powder and described the second mixed powder and obtain total mixed powder.
Step 400, get the starch of 2-3 weight portion, add purified water configuration starch slurry, described starch slurry and total mixed powder mix and blend are obtained to soft material.
Step 500, described soft material is fabricated to and dryly after soft material granule obtains mixed composition granule.
Particularly, when preparing capsule, can granulate with 18 orders, with 60 degrees Celsius, be dried.
Step 600, the magnesium stearate of getting 0.5-1 weight portion, excessively mix with dried mixed composition granule after 80 mesh sieves and obtain total mixed material.
Preferably, incorporation time is chosen 10 minutes.
Step 700, utilize described total mixed material by predetermined dosage form useful in preparing drug formulations.
Particularly, when preparing capsule, step 700 specifically can comprise utilizes total mixed material to fill Capsules, preferably, can carry out filled capsules with the dosage of 0.5 gram every.
After filling, carry out the finished product that capsule polishing obtains described pharmaceutical preparation capsule.
This area is easily understood, and said method flow process also can be for the preparation of the pharmaceutical preparation described in embodiment tetra-.
The pharmaceutical preparation of preparing based on the present embodiment, it can effectively improve osteocyte propagation, improve bone density, alleviation and treatment arthralgia, effectively prevents and treat osteoporosis.
The embodiment of the present invention also provides having of embodiment mono-or embodiment bis-to increase the compound composition of bone density, alleviation and treatment arthralgia effect in the medicine of preparation Prevention and Treatment of Osteoporosis or the application in health food.
Compound composition by Application Example one or embodiment bis-has to be increased medicine or the health food of bone density and treatment arthralgia effect and can be widely used in the clinical treatment for osteoporosis, also can be for the health care maintenance to bone-loss.
Claims (9)
1. there is a compound composition that increases bone density, treatment bone joint pain effect, it is characterized in that, by the raw material of following weight portion, formed:
D-glucosamine sulphuric acid potassium salt 60-90 part, calcium carbonate 35-65 part, ossein 10-40 part, Fructus Psoraleae extract 10-25 part, phosphopeptide caseinate 2-8 part.
2. according to claim 1 have a compound composition that increases bone density, treatment bone joint pain effect, it is characterized in that, the raw material of following weight portion, consists of:
75 parts of D-glucosamine sulphuric acid potassium salt, 50 parts of calcium carbonate, 25 parts of osseins, 15 parts of Fructus Psoraleae extracts, 4 parts of phosphopeptide caseinates.
3. the compound composition with increase bone density, treatment bone joint pain effect according to claim 1, is characterized in that, contains percentage by weight and be more than or equal to 1% psoralen in described Fructus Psoraleae extract.
4. there is a pharmaceutical preparation that increases bone density, treatment bone joint pain effect, it is characterized in that, by the compound composition as described in any one in claim 1-3 and solid pharmacy adjuvant, formed; Described solid pharmacy adjuvant weight is no more than 25% of described pharmaceutical preparation weight.
5. the pharmaceutical preparation with increase bone density, treatment bone joint pain effect according to claim 4, is characterized in that, described pharmaceutical preparation is pill, granule, capsule, tablet or powder.
6. according to claim 4 have the pharmaceutical preparation that increases bone density, treatment bone joint pain effect, it is characterized in that described solid pharmacy accessory package draws together wherein any one or any two s' mixture of starch, dextrin, microcrystalline Cellulose, hydroxy methocel, magnesium stearate.
7. pharmaceutical preparation according to claim 4, is characterized in that, described solid pharmacy accessory package is drawn together starch and magnesium stearate.
8. a preparation method for pharmaceutical preparation as claimed in claim 7, is characterized in that, comprising:
Get the Fructus Psoraleae extract of 10-25 weight portion and the phosphopeptide caseinate of 2-8 weight portion, after mistake 80 mesh sieves, mix homogeneously obtains the first mixed powder respectively;
Get the ossein of 10-40 weight portion, the starch of 20-30 weight portion, excessively after 80 mesh sieves, mix homogeneously and obtain the second mixed powder with described the first mixed powder respectively;
Get the D-glucosamine sulphuric acid potassium salt of 60-90 weight portion, after pulverizing, cross 80 mesh sieves and obtain D-glucosamine sulphuric acid potassium salt powder; Get the calcium carbonate of 35-65 weight portion, excessively after 80 mesh sieves, mix with described D-glucosamine sulphuric acid potassium salt powder and described the second mixed powder and obtain total mixed powder;
Get the starch of 2-3 weight portion, add purified water configuration starch slurry, described starch slurry and total mixed powder mix and blend are obtained to soft material;
After described soft material is fabricated to soft material granule, dry acquisition mixed composition granule;
Get the magnesium stearate of 0.5-1 weight portion, excessively after 80 mesh sieves, mix with dried mixed composition granule and obtain total mixed material;
Utilize described total mixed material by predetermined dosage form useful in preparing drug formulations.
9. according to any one in claim 1-3, have and increase the compound composition of bone density effect in the medicine of preparation Prevention and Treatment of Osteoporosis, alleviation and treatment arthralgia or the application in health food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310507876.0A CN103520711A (en) | 2013-10-24 | 2013-10-24 | Formula composition and medicinal preparation with effects of increasing bone density and treating bone joint pain, preparation method of medicinal preparation and application of formula composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310507876.0A CN103520711A (en) | 2013-10-24 | 2013-10-24 | Formula composition and medicinal preparation with effects of increasing bone density and treating bone joint pain, preparation method of medicinal preparation and application of formula composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103520711A true CN103520711A (en) | 2014-01-22 |
Family
ID=49923296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310507876.0A Pending CN103520711A (en) | 2013-10-24 | 2013-10-24 | Formula composition and medicinal preparation with effects of increasing bone density and treating bone joint pain, preparation method of medicinal preparation and application of formula composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103520711A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104162150A (en) * | 2014-07-23 | 2014-11-26 | 北京中泰天和科技有限公司 | Composition having bone mineral density increasing function and preparation method thereof |
| CN104256589A (en) * | 2014-09-23 | 2015-01-07 | 陶玲云 | Joint health product |
| CN104288757A (en) * | 2014-09-23 | 2015-01-21 | 陶玲云 | Method for preparing joint health product |
| CN105054035A (en) * | 2015-08-23 | 2015-11-18 | 洛阳维尔健生物工程有限公司 | Health-care product capable of improving bone density and preparation method of health-care product |
| CN105380272A (en) * | 2015-12-08 | 2016-03-09 | 哈药集团三精制药有限公司 | Preparation method of tablet for increasing bone density |
| CN107467669A (en) * | 2017-09-05 | 2017-12-15 | 山东健康源生物工程有限公司 | A kind of ammonia sugar calcium health products and preparation method thereof |
| CN113713084A (en) * | 2018-02-08 | 2021-11-30 | 湖南易能生物医药有限公司 | Medicine and food dual purpose Chinese medicinal product for treating bone and joint pain and osteoporosis of middle aged and elderly people |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101428056A (en) * | 2008-12-16 | 2009-05-13 | 江西本草天工科技有限责任公司 | Health care formulation for improving osteoporosis of female in middle and old age and preparation method thereof |
| CN101695382A (en) * | 2009-10-30 | 2010-04-21 | 洛阳新春都生物制药有限公司 | Calcium supplementing preparation with functions of improving bones and joints |
| CN101856128A (en) * | 2010-03-23 | 2010-10-13 | 无锡市天赐康生物科技有限公司 | Health food for increasing bone density and preparation method thereof |
| CN102133395A (en) * | 2011-03-18 | 2011-07-27 | 上海海维生物科技有限公司 | Skeleton health-care product or medicinal composite and application thereof |
| CN102318835A (en) * | 2011-08-31 | 2012-01-18 | 石家庄中硕药业集团有限公司 | Composition for reducing bone loss and preparation method thereof |
| CN103039976A (en) * | 2012-12-05 | 2013-04-17 | 无锡市天赐康生物科技有限公司 | Healthcare food for increasing bone density and preparation method thereof |
-
2013
- 2013-10-24 CN CN201310507876.0A patent/CN103520711A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101428056A (en) * | 2008-12-16 | 2009-05-13 | 江西本草天工科技有限责任公司 | Health care formulation for improving osteoporosis of female in middle and old age and preparation method thereof |
| CN101695382A (en) * | 2009-10-30 | 2010-04-21 | 洛阳新春都生物制药有限公司 | Calcium supplementing preparation with functions of improving bones and joints |
| CN101856128A (en) * | 2010-03-23 | 2010-10-13 | 无锡市天赐康生物科技有限公司 | Health food for increasing bone density and preparation method thereof |
| CN102133395A (en) * | 2011-03-18 | 2011-07-27 | 上海海维生物科技有限公司 | Skeleton health-care product or medicinal composite and application thereof |
| CN102318835A (en) * | 2011-08-31 | 2012-01-18 | 石家庄中硕药业集团有限公司 | Composition for reducing bone loss and preparation method thereof |
| CN103039976A (en) * | 2012-12-05 | 2013-04-17 | 无锡市天赐康生物科技有限公司 | Healthcare food for increasing bone density and preparation method thereof |
Non-Patent Citations (5)
| Title |
|---|
| 丁学琨等: "美洛昔康肠道2次脉冲释药组合片的研制", 《中国新药杂志》 * |
| 刘振海等: "防治骨质疏松症常用单味中药实验研究概况", 《环球中医药》 * |
| 刘洪泉等: "雪莲果叶提取物降血糖口含片制备工艺研究", 《应用化工》 * |
| 宋芹等: "补骨脂提取物与罗非鱼鱼鳞胶原蛋白多肽抗骨质疏松的实验研究", 《中药药理与临床》 * |
| 王建华等: "补骨脂素对大鼠成骨细胞增殖与分化的影响", 《天然产物研究与开发》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104162150A (en) * | 2014-07-23 | 2014-11-26 | 北京中泰天和科技有限公司 | Composition having bone mineral density increasing function and preparation method thereof |
| CN104256589A (en) * | 2014-09-23 | 2015-01-07 | 陶玲云 | Joint health product |
| CN104288757A (en) * | 2014-09-23 | 2015-01-21 | 陶玲云 | Method for preparing joint health product |
| CN104256589B (en) * | 2014-09-23 | 2016-05-25 | 陶玲云 | A kind of joint care product |
| CN105054035A (en) * | 2015-08-23 | 2015-11-18 | 洛阳维尔健生物工程有限公司 | Health-care product capable of improving bone density and preparation method of health-care product |
| CN105380272A (en) * | 2015-12-08 | 2016-03-09 | 哈药集团三精制药有限公司 | Preparation method of tablet for increasing bone density |
| CN107467669A (en) * | 2017-09-05 | 2017-12-15 | 山东健康源生物工程有限公司 | A kind of ammonia sugar calcium health products and preparation method thereof |
| CN113713084A (en) * | 2018-02-08 | 2021-11-30 | 湖南易能生物医药有限公司 | Medicine and food dual purpose Chinese medicinal product for treating bone and joint pain and osteoporosis of middle aged and elderly people |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520711A (en) | Formula composition and medicinal preparation with effects of increasing bone density and treating bone joint pain, preparation method of medicinal preparation and application of formula composition | |
| CN103251671B (en) | A kind of composition and method of making the same containing Chinese medicine increasing bone density | |
| CN103083650B (en) | Composition with bone mineral density addition function, and preparation method as well as application of composition | |
| ES2439741T3 (en) | Composition comprising components of crustacean gastrolites, calcium carbonate and their use | |
| CN101856114B (en) | Health food with bone intensity enhancing function and preparation method thereof | |
| CN103798595A (en) | Healthcare food for increasing bone mineral density and preparation method thereof | |
| CN107349333B (en) | Composition with effect of increasing bone mineral density and preparation method and application thereof | |
| CN103141892A (en) | Cucumber seed beverage and preparation method and application thereof | |
| CN104127861B (en) | A kind of have pharmaceutical composition increasing bone density effect and preparation method thereof | |
| CN103735937B (en) | There is the medicine and health products promoting ferrous components to absorb and to enrich blood | |
| CN101292739B (en) | Health food having function of increasing bone substance density | |
| CN103238841B (en) | Food composition containing Maca and saussurea involucrata culture and application thereof | |
| CN104824677A (en) | Bone density increase health food and preparation method thereof | |
| CN104146260A (en) | Health-care food for improving bone density and preparation method thereof | |
| CN103349674B (en) | Tortoise shell rana japonica oil composition for increasing bone density and preventing osteoporosis | |
| CN1209133C (en) | Medicine for preventing and curing rachitis and osteoporosis and method for preparing the same | |
| CN101229273A (en) | Medlar multi-vitamins calcium tablet | |
| CN102626463A (en) | Natural medicine compound for increasing bone mineral density and preventing and treating osteoporosis | |
| CN108968075A (en) | It is a kind of improve bone health composition and its application | |
| CN103768434A (en) | Traditional Chinese medicine for enhancing laying rate of laying hens and preparation method thereof | |
| CN104001157A (en) | Compound preparation for preventing and treating osteoporosis and preparation method thereof | |
| CN105998370A (en) | Composition for treating and preventing osteoporosis | |
| CN110201023A (en) | A kind of prevention and treatment osteoporosis composition | |
| CN105996059A (en) | Composition for increasing bone mineral density | |
| CN101444552B (en) | Chinese medicinal preparation for treating osteoporosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140122 |